Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey

Ünal, Nalan Gülşen; Özütemiz, Ömer; Teki̇n, Fati̇h; Turan, Ilker; Osmanoğlu, Necla

doi:10.5152/tjg.2018.18221

Cited by 10 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the initial search, a total of 618 related articles were obtained according to the research strategy. We also obtained 7 articles from the reference lists and citation indices of the included studies[ 29 , 31 , 34 , 38 , 41 , 43 , 44 ]. Twenty articles[ 14 , 29 - 32 , 34 - 41 , 45 - 51 ] that might be eligible for inclusion were reviewed.…”

Section: Resultsmentioning

confidence: 99%

“…We also obtained 7 articles from the reference lists and citation indices of the included studies[ 29 , 31 , 34 , 38 , 41 , 43 , 44 ]. Twenty articles[ 14 , 29 - 32 , 34 - 41 , 45 - 51 ] that might be eligible for inclusion were reviewed. Among them, 12 articles met our inclusion criteria (Figure 1 )[ 14 , 29 , 31 , 32 , 34 - 41 ].…”

Section: Resultsmentioning

confidence: 99%

“…Studies were excluded if (1) They were review articles, case reports, letters, or laboratory studies; (2) Important data of interest were missing; (3) Republished literature; and (4) Not English literature. Twelve eligible studies were finally included in our meta-analysis[ 14 , 29 , 31 , 32 , 34 - 41 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis

He¹,

Chen²,

Jing³

et al. 2022

WJGO

View full text Add to dashboard Cite

BACKGROUND Inflammatory bowel disease (IBD) patients with post-inflammatory polyps (PIPs) may carry an increased risk of colorectal neoplasia (CRN) including dysplasia and cancer. Current guidelines recommend active colonoscopy follow-up for these patients. However, the evidence for guidelines is still poor. In addition, some recent high-quality reports present a different view, which challenges the current guidelines. We hypothesize that IBD patients with PIPs are at increased risk of CRN. AIM To evaluate the risk of CRN in IBD patients with and without PIPs. METHODS A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was performed to identify studies that compared the risk of CRN in IBD patients with and without PIPs. In addition, we screened the reference lists and citation indices of the included studies. Quality assessment was performed using the Newcastle–Ottawa Scale. Pooled odds ratio (OR) was calculated using the random-effects model to explore the final pooled effect size of the included studies and determine whether PIPs increase the risk of CRN. Sensitivity analysis, subgroup analysis, and assessment of publication bias were performed to examine the sources of heterogeneity. RESULTS Twelve studies with 5819 IBD patients, including 1281 (22.01%) with PIPs, were considered eligible for this meta-analysis. We found that IBD patients with PIPs were at an increased risk of CRN as compared to those without PIPs [OR 2.01; 95% confidence interval (CI): 1.43–2.83]. The results were similar when colorectal cancer was used as the study endpoint (OR 2.57; 95%CI: 1.69–3.91). Furthermore, the risk of CRN was still increased (OR 1.80; 95%CI: 1.12–2.91) when restricted to ulcerative colitis patients. Heterogeneity was high among the included studies ( I ² = 75%). Subgroup analysis revealed that the high heterogeneity was due to the study design. Sensitivity analysis showed that the main statistical outcomes did not essentially change after excluding any one of the included studies. No significant publication bias was found in the funnel plots. CONCLUSION IBD patients with PIPs have an increased risk of CRN as compared with those without PIPs, which support the current guidelines. However, a high-quality randomized controlled trial is warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis

He¹,

Chen²,

Jing³

et al. 2022

WJGO

View full text Add to dashboard Cite

show abstract

“…Incidence of colorectal cancer in IBD is altered accordingly to the disease duration that proved to be an important risk factor [21]. Based on a retrospective cohort study, which was published in 2019, the cumulative risk of CRC was 0.3% at 10 years, 1.3% at 20 years, and 5.9% at 30 years after the onset of UC [22]. Previous studies differ in the exact incidence rate, and older ones estimated higher values than recent reports [21,23], but they all underline a positive correlation between IBD and CRC [16,24,25].…”

Section: Risk Factors Of Crc In Ibdmentioning

confidence: 99%

The Role of MicroRNAs upon Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease

Boros

Nagy

2019

Cells

View full text Add to dashboard Cite

Increasing evidence suggest the significance of inflammation in the progression of cancer, for example the development of colorectal cancer in Inflammatory Bowel Disease (IBD) patients. Long-lasting inflammation in the gastrointestinal tract causes serious systemic complications and breaks the homeostasis of the intestine, where the altered expression of regulatory genes and miRNAs trigger malignant transformations. Several steps lead from acute inflammation to malignancies: epithelial-to-mesenchymal transition (EMT) and inhibitory microRNAs (miRNAs) are known factors during multistage carcinogenesis and IBD pathogenesis. In this review, we outline the interactions between EMT components and miRNAs that may affect cancer development during IBD.

show abstract

“…Un reciente estudio realizado en Turquía, que analiza la prevalencia de CCR y displasia en 801 pacientes con CU, muestra una prevalencia de CCR de 0,7% y de displasia de 0,85%, y una incidencia acumulada de CCR de 0,3% a los 10 años, 1,3% a los 20 años y de 5,9% a los 30 años 5 . El registro nacional sueco con datos de 5.886 pacientes con CU muestra que únicamente el 0,8% presenta cáncer de recto después de realizarse una colectomía subtotal con preservación del recto 6 .…”

Section: Introductionunclassified

Resecciones colorrectales segmentarias en pacientes con colitis ulcerosa y displasia o adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

Introducción: El tratamiento estándar para los pacientes con colitis ulcerosa y displasia o adenocarcinoma de colon ha sido la proctocolectomía total, lo que conlleva una morbilidad y una reducción en la calidad de vida significativa.Materiales y métodos: Se hace un análisis retrospectivo de 5 pacientes con colitis ulcerosa a los que se realiza una resección segmentaria por displasia o adenocarcinoma.Resultados: La mediana de edad al diagnóstico de colitis ulcerosa y de la neoplasia fue de 56 y 62 años respectivamente. El tiempo de evolución de la enfermedad fue de 1 a 13 años. La mediana de seguimiento postoperatorio fue de 57 meses apareciendo en uno de los pacientes un nuevo foco de displasia.Conclusiones: En determinados pacientes seleccionados, las resecciones segmentarias podrían ser una opción segura si tienen buen control de la enfermedad, escasa actividad inflamatoria, pocos años de evolución y que puedan realizar un adecuado seguimiento posterior.

show abstract

Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey

Cited by 10 publications

References 33 publications

Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis

Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis

The Role of MicroRNAs upon Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease

Resecciones colorrectales segmentarias en pacientes con colitis ulcerosa y displasia o adenocarcinoma

Contact Info

Product

Resources

About